An Overview of the Randomized Placebo-Controlled Trials of Chinese Herbal Medicine Formula Granules

Table 4

Comparison of the effectiveness rate between CHM formula granules and placebo.

Study ID	Treatment		Placebo		P value
	n/N	%	n/N	%
HBV carrier: Reduction of within-group HBV DNA levels by more than 2lgIU/ml
He JS 2012	38/174	21.84	5/93	5.38	0.001
Li HZ 2012	37/191	19.37	4/94	4.26	0.002
Ni W 2015	6/40	15.00	2/20	10.00	0.59
Peng DT 2016	15/44	34.09	2/23	8.70	0.04
Xing YF 2012	37/191	19.37	9/187	4.81	<0.001
Meta-analysis RR and 95% CI: 4.64 ; I^2 = 0%
Non-alcoholic fatty liver disease: Reduction in ALT by >50% after 12-week treatment
Cheng Y 2017	33/40	82.50	21/40	52.00	0.006
Depression: Reduction in Edinburgh Postnatal Depression Scale (EPDS)≥50
Xu F 2013-1	40/50	80.00	24/50	48.00	0.001
Xu F 2013	35/45	77.78	18/45	40.33	0.0004
Fever: Reduction in fever, and resolution of some cold symptoms
Cheng Y 2016	39/41	95.12	26/40	65.85	0.003
Xie JH 2017	45/48	93.75	44/48	91.67	0.7
Meta-analysis(random) RR and 95% CI: 3.78 ; I^2 = 70%
Migraine: Reduction in frequency/duration of headaches by >50% after 12-week treatment
Fu CH 2014	101/129	78.29	49/64	76.56	0.79
Fu CH 2014	92/129	71.32	46/64	71.88	0.94
AIDS: Increase in CD4 levels by >30 after 6-month treatment
Li Y 2012	14/36	38.89	6/36	16.67	0.04